Business Wire

FLATEXDEGIRO-AG

31.3.2022 16:09:13 CEST | Business Wire | Press release

Share
flatexDEGIRO offers robo-advisory through partnership with Whitebox

flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR), Europe's largest and fastest growing online broker for retail investors, today announced the signing of a Memorandum of Understanding (MoU) to extend its long-standing B2B partnership with digital wealth manager Whitebox, one of the leading independent robo-advisors for retail investors. Together, flatexDEGIRO and Whitebox will offer a fully digital investment solution to flatexDEGIRO's customers, aimed to start at flatex Germany in summer 2022.

Frank Niehage, CEO of flatexDEGIRO: "The extended partnership supports flatexDEGIRO's strategic priority to provide millions of retail investors in Europe with the best online brokerage platform in terms of product, platform and price. It enables us to offer our customers access to an additional, highly attractive and comfortable way of investing. This benefits in particular customers who were previously less active in trading. In addition, it enables us to address new client groups that are generally looking for support in accessing the capital markets on a sustainable, long-term basis. Offering digital wealth management in form of robo-advisory is the next, logical step in verticalizing our unique European brokerage platform."

Salome Preiswerk, Founder and Managing Director of Whitebox: "We are very excited about the opportunities that arise from the strategic partnership. Our aim is to offer investments that are tailored to individual needs, simple, transparent, cost-effective - and of high quality. Expanding our reach with a trusted partner such as flatexDEGIRO to potentially several million retail investors across Europe means a big step forward for us."

Muhamad Chahrour, CFO of flatexDEGIRO and CEO of DEGIRO: "With flatexDEGIRO, we retailise capital market access. A wide range of products, low prices, easy handling. However, many customers still need guidance when it comes to investment. Be it due to indecision, lack of ideas or the desire for a simple, tailor-made product. ETF savings plans are an important step in the right direction, but clients still have to search for, analyse and select the right ETF themselves. Many customers have asked us for a simple solution - we now deliver this in partnership with Whitebox. In a few clicks, everyone can create their own portfolio - and benefit sustainably from Europe's easiest access to capital markets."

flatexDEGIRO and Whitebox partner in the B2B space for more than seven years already. Over these years, Whitebox has been awarded best robo-advisor in Germany several times with especially strong ratings on product offer, service quality and attractiveness of its pricing model [1] . This strategic fit as well as the trustful relationship and deep mutual understanding built over time makes Whitebox the perfect partner for flatexDEGIRO to offer this ancillary service to its customers in a seamless and intuitive way. After the successful launch at flatex, flatexDEGIRO will look into expanding the offering to all DEGIRO customers.

[1] https://www.whitebox.eu/hubfs/Testsieger_EuroamSonntag.pdf

About flatexDEGIRO AG

flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR) operates a leading and fastest growing online brokerage platforms in Europe. Based on modern, in-house state-of-the-art technology customers of the flatex and DEGIRO brands are offered a wide range of independent products with execution at top TIER 1 exchanges. Its technological edge as well as high levels of efficiency and strong economies of scale allows flatexDEGIRO to continuously improve its value proposition to clients, including commission-free brokerage.

With more than 2 million customer accounts and over 91 million securities transactions settled in 2021, flatexDEGIRO is the largest retail online broker in Europe. In a time of bank consolidation, low interest rates and digitalization, flatexDEGIRO is ideally positioned for further growth. Within the next five years, flatexDEGIRO aims to grow its customer base to 7-8 million customer accounts, settling 250-350 million transactions per year - even in years with low volatility.

More information via https://www.flatexdegiro.com/en

About Whitebox

Whitebox is one of the leading independent digital asset managers in Germany. The company offers several investment strategies. In doing so, Whitebox invests primarily in undervalued asset classes that are mapped with low-cost, exchange-traded index funds (ETFs). When optimising client portfolios, Whitebox relies on the latest findings from financial market research. The digital asset manager has been active on the German market since the beginning of 2016 and has already received several awards as Germany's best robo-advisor.

More information via https://www.whitebox.eu

Language:

English

Company:

flatexDEGIRO AG

 

Rotfeder-Ring 7

 

60327 Frankfurt / Main

 

Germany

Phone:

+49 (0) 69 450001 0

E-mail:

ir@flatexdegiro.com

Internet:

www.flatexdegiro.com

ISIN:

DE000FTG1111

WKN:

FTG111

Indices:

SDAX

Listed:

Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Munich, Stuttgart, Tradegate Exchange

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye